Onduo, a joint venture of Sanofi (NYSE:SNY) and Verily, is reportedly working to develop a platform that brings together medical devices, software and support from healthcare experts to help people manage their Type II diabetes.
The platform is slated to launch as a pilot program for certain U.S.-based payers and providers in early-2018.
“Roughly half of 7.5 million people in the U.S. who use insulin to manage their diabetes are not reaching their treatment goals, and millions more who could benefit from insulin therapy either avoid it or discontinue it,” Glytec’s CMO, Dr. Andrew Rhinehart, said in prepared remarks. “Fixing this decades-old problem represents one of the greatest opportunities to improve the quality and cost of diabetes care.”
“Everyone responds to insulin differently, so the key to optimizing insulin therapy is to ensure that dosing is personalized, timely and accurate, which is exactly what Glucommander Outpatient helps providers achieve,” he added.
The company’s cloud-based insulin management software has been evaluated in multiple studies, Glytec touted. According to data from those studies, patients using Glucommander hit their glucose targets in an average of 12.5 days and experienced a 2.5% drop in A1C over a year-long period.
“We are very excited to partner with Onduo and play an important role in this integrated care solution,” Glytec’s president and CEO, Bob Leonard, said. “We firmly believe that this type of best-of-breed matrix approach — synthesizing the most essential and innovative technologies and services – will emerge as the most potent way to drive improvements in the quality, safety and cost of care for people living with diabetes.”